Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in treatment-resistant depression
NCT04141904Phase 2Terminated
- Sponsor
- University of Oxford
- Start
- Feb 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Tofacitinib Arm with Placebo Arm (2 arms). Primary endpoint: Facial Expression Recognition Task. Started Feb 2020; status: terminated.
02
Drugs
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04141904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04141904.